Your browser is no longer supported. Please, upgrade your browser.
Settings
TENX Tenax Therapeutics, Inc. daily Stock Chart
TENX [NASD]
Tenax Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.12 Insider Own2.40% Shs Outstand1.80M Perf Week-45.50%
Market Cap2.18M Forward P/E- EPS next Y-2.63 Insider Trans0.00% Shs Float1.15M Perf Month-71.60%
Income-5.90M PEG- EPS next Q-0.88 Inst Own12.20% Short Float6.14% Perf Quarter-76.73%
Sales- P/S- EPS this Y79.90% Inst Trans0.92% Short Ratio0.25 Perf Half Y-81.75%
Book/sh3.38 P/B0.36 EPS next Y- ROA-77.30% Target Price15.00 Perf Year-84.08%
Cash/sh2.67 P/C0.45 EPS next 5Y- ROE-84.50% 52W Range1.32 - 12.63 Perf YTD-87.65%
Dividend- P/FCF- EPS past 5Y45.10% ROI- 52W High-90.42% Beta0.51
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low-8.16% ATR0.61
Employees7 Current Ratio10.00 Sales Q/Q- Oper. Margin- RSI (14)19.18 Volatility72.95% 28.77%
OptionableNo Debt/Eq0.00 EPS Q/Q-19.80% Profit Margin- Rel Volume1.94 Prev Close1.33
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume278.46K Price1.21
Recom1.00 SMA20-58.22% SMA50-70.58% SMA200-78.88% Volume540,717 Change-9.02%
May-18-17Upgrade Ladenburg Thalmann Neutral → Buy
Dec-16-14Initiated MLV & Co Buy $7
Nov-18-14Initiated WallachBeth Buy $12
Dec-11-18 04:00PM  Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering Business Wire -9.02%
Dec-07-18 01:02PM  Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering Business Wire -17.26%
Nov-26-18 11:00AM  TENX: We Have Liftoff: HELP Site Activated Zacks Small Cap Research -19.69%
Nov-21-18 03:21PM  Heat Biologics Takes Beating After Pricing $12 Million Stock Offering TheStreet.com -19.44%
Nov-19-18 08:00AM  Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial Business Wire +5.00%
Nov-07-18 04:20PM  TENX: Tenax S-1 Filing Zacks Small Cap Research -19.06%
Oct-01-18 09:04AM  How Should You Think About Tenax Therapeutics Incs (NASDAQ:TENX) Risks? Simply Wall St. -11.98%
Sep-20-18 08:30AM  Tenax Therapeutics to Present at Upcoming Investor Conferences Business Wire +14.57%
Sep-04-18 10:45AM  TENX: 3Q Start to Pulmonary Hypertension Trial Zacks Small Cap Research
Aug-29-18 08:30AM  Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference Business Wire
Aug-28-18 08:30AM  Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients Business Wire
Jun-11-18 07:24PM  Has Tenax Therapeutics Inc (NASDAQ:TENX) Improved Earnings Growth In Recent Times? Simply Wall St.
Jun-07-18 09:30AM  TENX: Tenax 1Q:18 Results Zacks Small Cap Research
Jun-05-18 04:30PM  Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO Business Wire
Jun-04-18 08:37AM  While merger a possibility, Tenax pushes forward with new trial American City Business Journals
Jun-01-18 08:30AM  Tenax Therapeutics Announces Study Design for Phase 2 Trial of Levosimendan in PH-HFpEF Patients Business Wire
May-24-18 02:27PM  Why You Need To Look At This Factor Before Buying Tenax Therapeutics Inc (NASDAQ:TENX) Simply Wall St.
Apr-13-18 12:55PM  How Do Analysts See Tenax Therapeutics Inc (NASDAQ:TENX) Performing In The Next Couple Of Years? Simply Wall St.
Apr-12-18 10:10AM  TENX: New Indication for Levosimendan Zacks Small Cap Research
Apr-06-18 01:36PM  Finding Breakouts And Avoiding Fakeouts In A Market At War With Itself Benzinga
08:21AM  Amid strategic review, Tenax gets go-ahead from FDA American City Business Journals
Apr-05-18 02:43PM  Benzinga's Top Analyst Calls From April 5, 2018 Benzinga
08:05AM  This $3 Medical Device Stock be Worth $9-14 with Impending Product Launch ACCESSWIRE
Apr-04-18 10:23AM  Tenax Therapeutics Incs (NASDAQ:TENX) Shift From Loss To Profit Simply Wall St. +46.43%
08:00AM  Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients Business Wire
Mar-14-18 08:00AM  Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Business Wire -5.25%
Mar-08-18 02:11PM  With A -97.88% Earnings Drop Lately, Did Tenax Therapeutics Inc (NASDAQ:TENX) Underperform Its Industry? Simply Wall St.
Mar-02-18 08:10AM  Todays Research Reports on Stocks to Watch: Novavax and Tenax Therapeutics ACCESSWIRE -27.36%
Mar-01-18 08:30AM  Tenax Therapeutics Announces New Scientific Publication of Preclinical Data Provides Additional Evidence of Levosimendan Treatment Effects in Pulmonary Hypertension Business Wire +128.45%
Feb-23-18 08:00AM  Tenax Therapeutics Announces Reverse Stock Split Business Wire -25.74%
Feb-06-18 08:30AM  World-Recognized Experts Join Tenax Therapeutics Scientific Advisory Board to Guide New Phase 2 Study Business Wire
Jan-16-18 07:45AM  Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies Business Wire -12.42%
Jan-02-18 08:09PM  Does Zero-Debt Make Tenax Therapeutics Inc (NASDAQ:TENX) A Financially Strong Company? Simply Wall St. -8.67%
Aug-02-17 07:00AM  TENX: FDA Response on Levosimendan Zacks Small Cap Research
Jul-28-17 05:00PM  Tenax Therapeutics Provides Regulatory Update on Levosimendan Business Wire
May-16-17 04:33PM  Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission Business Wire
Apr-10-17 03:25PM  Tenax CEO resigns, company to review 'strategic alternatives' American City Business Journals
Apr-05-17 05:30PM  Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update Business Wire
Mar-27-17 09:00AM  TENX: 2016 Results; Subgroup Analysis Shows CABG Survival Benefit Zacks Small Cap Research
Mar-22-17 01:04PM  TENAX THERAPEUTICS, INC. Financials -12.04%
Mar-21-17 07:07AM  Q4 2016 Tenax Therapeutics Inc Earnings Release - Before Market Open
06:00AM  Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update Business Wire
Mar-20-17 04:05PM  Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017 Accesswire -14.73%
Mar-17-17 05:02PM  TENAX THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
Mar-16-17 04:34PM  TENAX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-15-17 04:31PM  Tenax Therapeutics to Discuss Year-End 2016 Financial Results and Provide Business Update Business Wire
Feb-08-17 04:50PM  TENX: Tenax Reports LEVO-CTS Topline Results Zacks Small Cap Research
Jan-31-17 04:04PM  Under Armour, Rite Aid Fall into Tuesdays 52-Week Low Club 24/7 Wall St. -76.41%
09:00AM  Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery Business Wire
Jan-30-17 09:45AM  Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Tenax Therapeutics and ZIOPHARM Oncology Accesswire -9.72%
Jan-27-17 09:07AM  Tenax Therapeutics Inc (TENX) Might Be A Discount Opportunity Ahead Of January Release Insider Monkey +19.34%
Jan-10-17 08:05AM  Tenax Therapeutics, Inc. Review of Clinical Trials and Financials Accesswire -7.23%
Dec-16-16 06:15AM  Is KemPharm Inc (KMPH) A Good Stock To Buy? at Insider Monkey
Nov-21-16 11:15AM  TENX: LEVO-CTS Enrolment Complete; Anticipate January Topline Readout
Nov-18-16 08:30AM  Tenax Therapeutics Announces Completion of Enrollment for Phase 3 LEVO-CTS Trial in Cardiac Surgery Business Wire
Nov-10-16 07:07AM  Q3 2016 Tenax Therapeutics Inc Earnings Release - Time Not Supplied
06:06AM  Tenax Therapeutics reports 3Q loss
06:00AM  Tenax Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update Business Wire
Nov-09-16 04:20PM  Investor Calendar Invites You to the Tenax Therapeutics Third Quarter 2016 Business Review and Update on Thursday, November 10, 2016 Accesswire
04:09PM  TENAX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-03-16 04:30PM  Tenax Therapeutics to Discuss Third Quarter 2016 Financial Results and Provide Business Update Business Wire
Oct-17-16 11:00AM  TENX: LeoPARDS Trial Fails Endpoints; Year End 2016 Readout for LEVO-CTS.
Oct-07-16 02:13PM  Heres What Happened With Alnylam Pharmaceuticals, Inc. (ALNY) and Tenax Therapeutics Inc (TENX) at Insider Monkey
Oct-05-16 10:30AM  Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan Business Wire
Aug-11-16 04:00PM  TENX: Higher Costs in FY:16; Dual Readouts in 4Q:16 Maintaining $10 Target
07:07AM  Q2 2016 Tenax Therapeutics Inc Earnings Release - Before Market Open
06:00AM  Tenax Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update Business Wire
Aug-09-16 04:35PM  TENAX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Aug-03-16 05:00PM  Tenax Therapeutics to Discuss Second Quarter 2016 Financial Results and Provide Business Update Business Wire
Jun-16-16 05:17PM  TENAX THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-08-16 11:00AM  TENX: Phase 3 Readout Expected by Summers End
May-19-16 07:07AM  Q1 2016 Tenax Therapeutics Inc Earnings Release - Before Market Open
06:37AM  TENAX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
06:30AM  Tenax Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update Business Wire
May-10-16 04:31PM  TENAX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
07:30AM  Tenax Therapeutics to Discuss First Quarter 2016 Financial Results and Provide Business Update Business Wire
Apr-15-16 04:00PM  TENX: Proven Compound in Late Phase III Trials
Mar-16-16 06:00AM  Tenax Therapeutics Announces 2015 Transitional Report and Provides Corporate Update Business Wire
Mar-09-16 05:30PM  Tenax Therapeutics to Provide 2015 Transitional Report and Business Update Business Wire
Mar-01-16 05:30PM  Tenax Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference Business Wire
Feb-04-16 07:30AM  Tenax Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference Business Wire
Feb-02-16 10:45AM  TENX: Patient Enrollment Accelerates in Phase 3 LEVO-CTS
Feb-01-16 01:28PM  Tenax Therapeutics Provides Update of Phase 3 LEVO-CTS Trial for LCOS Business Wire
07:40AM  Tenax Therapeutics Provides Update of Phase 3 LEVO-CTS Trial for LCOS at noodls
Dec-22-15 01:39PM  Corporate Document-Board of Directors for TENAX Therapeutics, Inc. at Company Spotlight
10:15AM  TENX: Enrollment Complete for Levosimendan in Septic Shock LeoPARDS Trial
07:30AM  Tenax Therapeutics Highlights Completion of Enrollment for LeoPARDS Trial by Imperial College London Business Wire
Dec-21-15 03:50PM  TENX: Enrollment Picks Up for Phase 3 LEVO-CTS in LCOS as Phase 2b LeoPARDS in Septic Shock Nears Completion
Dec-15-15 12:12PM  Edited Transcript of TENX earnings conference call or presentation 15-Dec-15 1:30pm GMT
07:07AM  Q2 2016 Tenax Therapeutics Inc Earnings Release - Time Not Supplied
06:00AM  Tenax Therapeutics Announces Second Quarter Fiscal Year 2016 Financial Results Business Wire
Dec-10-15 05:37PM  Tenax Therapeutics reports 2Q loss
04:41PM  TENAX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Dec-08-15 04:30PM  Tenax Therapeutics to Provide Corporate Update and Discuss Second Quarter Fiscal Year 2016 Financial Results on December 15, 2015 Business Wire
Dec-07-15 11:28AM  Is Tenax Therapeutics Inc (TENX) Going to Burn These Hedge Funds? at Insider Monkey
Nov-27-15 09:26AM  Is The McClatchy Company (MNI) A Good Stock To Buy? at Insider Monkey
Nov-24-15 05:37PM  Should You Buy Shares of Covisint Corp (COVS)? at Insider Monkey
Oct-08-15 04:00PM  TENX: FDA Approves Phase 3 LEVO-CTS Protocol Amendment
07:30AM  Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan Business Wire
Sep-22-15 07:30AM  Tenax Therapeutics to Present at Ladenburg Thalmann 2015 Healthcare Conference Business Wire
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BLANCK RONALD RDirectorDec 18Buy0.4512,9505,88720,099Dec 20 09:50 AM